I-Corps: Polymeric Antibiotics for Drug-Resistant Infections

I-Corps：用于耐药感染的聚合抗生素

• 批准号: 1761711
• 负责人: Young Jik Kwon
• 金额: $ 5万
• 依托单位: University of California-Irvine
• 依托单位国家: 美国
• 项目类别: Standard Grant
• 财政年份: 2018
• 资助国家: 美国
• 起止时间: 2018-01-01 至 2019-06-30
• 项目状态: 已结题
• 来源: https://www.nsf.gov/awardsearch/showAward?AWD_ID=1761711&HistoricalAwards=false
• 关键词: Corps; Polymeric; Antibiotics; Drug; Resistant

The broader impact/commercial potential of this I-Corps project is providing a possible paradigm shift in antimicrobial therapy and in treating antibiotic resistant bacteria in a multitude of fields including healthcare, agriculture, water treatment, and veterinary. The ability to directly target drug resistant strains of various microbes can provide a vital impact on the state of global medicine. The CDC estimates more than 2 million people become infected with antibiotics resistant bacteria yearly, with at least 23,000 deaths due to antibiotic resistant infections. The use and availability of a natural nanomaterial that can innately affect the growth of various strains of microbes will enable wider access to antimicrobial applications. Aside from this potential for direct use, nano-antibiotics can also possibly be used to treat water systems, enabling a broad new market application.This I-Corps project stems from the core technology which enables selective targeting of infections inside human patients while denying the bacteria access to the traditional mechanisms through which drug resistance develops. The aim is to address the need for modern solutions to drug-resistant infections with engineered nano-antibiotics that are capable of reversing drug resistance in bacteria. These nano-antibiotics combine the genetic specificity of nucleic acids with a physically-active vector with therapeutic capability. A stimuli-responsive function is added to allow the nanoparticle to be tunable to specific infections as needed, while maintaining a wide-spectrum usability. This therapeutic strategy is unique not just because gene silencing is used to remove drug resistant properties from multi-drug resistant bacteria, a delivery vector that has the capability to kill the microbe is also used. This approach is generalizable, and can potentially be implemented to treat any bacterial infection that has become resistant to conventional antibiotics.

这个I-Corps项目的更广泛的影响/商业潜力为抗菌治疗和治疗包括医疗保健，农业，水处理和兽医在内的众多领域的抗生素耐药性细菌提供了可能的范式转变。直接靶向各种微生物的耐药菌株的能力可以对全球医学状况产生至关重要的影响。CDC估计，每年有超过200万人感染抗生素耐药性细菌，至少有23，000人死于抗生素耐药性感染。天然纳米材料的使用和可用性可以天生影响各种微生物菌株的生长，这将使抗菌应用更广泛。 除了这种直接使用的潜力，纳米抗生素还可以用于处理水系统，从而实现广泛的新市场应用。这个I-Corps项目源于核心技术，该技术可以选择性地靶向人类患者体内的感染，同时阻止细菌进入产生耐药性的传统机制。其目的是用能够逆转细菌耐药性的工程纳米抗生素来解决耐药性感染的现代解决方案的需求。这些纳米抗生素将核酸的遗传特异性与具有治疗能力的物理活性载体联合收割机相结合。增加了刺激响应功能，以允许纳米颗粒根据需要对特定感染进行调节，同时保持广谱可用性。这种治疗策略是独特的，不仅因为基因沉默被用来消除多重耐药细菌的耐药性，还使用了一种能够杀死微生物的递送载体。这种方法是可推广的，并且可以潜在地实施以治疗对常规抗生素具有耐药性的任何细菌感染。